Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 26:15:1435-1445.
doi: 10.2147/CCID.S357178. eCollection 2022.

Management of Atopic Dermatitis in Adults in Saudi Arabia: Consensus Recommendations from the Dermatological Expert Group

Abdullah Alakeel  1 , Afaf Al Sheikh  2   3 , Ali A Alraddadi  4   5   6 , Khalid Mohammed Alattas  7 , Maha Aldayel  8 , Mohammed Abdulaziz Alajlan  9 , Mohammed Al-Haddab  1 , Mohammad Almohideb  3   10 , Mohamed Fatani  11 , Issam R Hamadah  12 , Ruaa Alharithy  13   14 , Yousef Binamer  15   16 , Kim Papp  17 , Ahmed Elaraby  18
Affiliations

Management of Atopic Dermatitis in Adults in Saudi Arabia: Consensus Recommendations from the Dermatological Expert Group

Abdullah Alakeel et al. Clin Cosmet Investig Dermatol. .

Abstract

Background: Atopic dermatitis (AD) is a long-term, pruritic, recurrent, systemic, inflammatory skin disorder. In the Middle East region, the burden of AD is understudied, and there is a dearth of AD guideline documents for practitioners.

Methods: An expert panel meeting, encompassing 12 dermatologists from the Kingdom of Saudi Arabia (KSA), was congregated to develop evidence- and experience-based consensus recommendations for AD management, especially in adults in KSA. They completed a questionnaire with seven clinical statements, and a consensus was defined when the responses of ≥75% of participants coincided.

Results: The expert recommendations were as follows: American Association of Dermatology guidelines are to be followed for defining AD; Eczema Area and Severity Index or SCORing atopic dermatitis index may be used to quantify the disease severity; Dermatology Life Quality Index may be used to determine the impact of AD on patients' quality of life; Atopic Dermatitis Control Tool may be used to assess long-term disease control in AD patients; and the European guidelines are to be followed for the management of AD. In AD patients who are inadequately controlled with topical or systemic therapies, the preferred systemic agent for use either alone or in combination with topical treatments is dupilumab, cyclosporine, methotrexate, phototherapy, or other available systemic treatments that may include mycophenolate mofetil or oral corticosteroids.

Conclusion: These expert recommendations assist physicians by providing a reference framework for optimal care of adult AD patients.

Keywords: Dermatology Life Quality Index; Eczema Area and Severity Index; SCORing atopic dermatitis; atopic dermatitis.

PubMed Disclaimer

Conflict of interest statement

Abdullah Alakeel, Afaf Al Sheikh, Ali A. Alraddadi, Maha Aldayel, Mohammed Abdulaziz Alajlan, Mohammed Al-Haddab, Issam R Hamadah, Ruaa Alharithy, Yousef Binamer, and Kim Papp received honoraria for attending the advisory board meeting; however, none of the authors were paid for the publication of this manuscript. Khalid Mohammed Alattas, Mohammad Almohideb, Mohamed Fatani, and Ahmed Elaraby have nothing to disclose. Dr Yousef Binamer reports personal fees from Sanofi, AbbVie, and Eli Lilly, during the conduct of the study. Dr Kim Papp reports grants and personal fees from AbbVie, Dermavant, Eli Lilly, Galderma, Incyte, Leo, and Sanofi-Aventis/Genzyme, personal fees from Arcutis, and grants from Galapagos and Pfizer, during the conduct of the study. The authors report no other potential conflicts of interest in relation to this work.

Figures

Figure 1
Figure 1
Flowchart representation of the meeting plan and consensus development.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23:S115–S123. - PubMed
    1. Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4:1. doi:10.1038/s41572-018-0001-z - DOI - PubMed
    1. Wollenberg A, Christen‐Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venerol. 2020;34:2717–2744. doi:10.1111/jdv.16892 - DOI - PubMed
    1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396:345–360. doi:10.1016/S0140-6736(20)31286-1 - DOI - PubMed
    1. Al-Afif KAM, Buraik MA, Buddenkotte J, et al. Understanding the burden of atopic dermatitis in Africa and the Middle East. Dermatol Ther. 2019;9:223–241. doi:10.1007/s13555-019-0285-2 - DOI - PMC - PubMed